Want to get your biotech seen by investors? Create a brand presence early

After years of hard work, you’re finally ready: your small team has developed something special and you’ve got the results you wanted. Now you’re at a crossroad and need the help of someone bigger to move it forward, where do you go from here?

It’s no secret that many of big pharma’s blockbuster drugs are in-licensed or acquired from smaller biotech companies which haven’t got the money, experience or resources to get their inventions to a global scale and stage. More than 50% of big pharma’s pipelines are sourced from smaller companies’ innovations. Around 30% of clinical assets have been in-licensed from China alone, according to recent studies. So, in a win-win (well sort of) arrangement, big pharma fill their pipelines, and the smaller companies get to see the assets they’ve worked hard on reach the market and, more importantly, make a difference in patients’ lives.

According to DealForma, in the last decade more than 4,000 biopharma companies were founded. With so many companies promising the next-best-thing, it’s important to stand out to potential partner companies by getting yourself seen as a company to watch or as one of the most promising start ups. This recognition will make you more visible and more lucrative to new biopharma or investment partners.

Many biotechs face challenges like this. They want to raise their profile globally, explain their company’s mission, describe their unique ethos and proposition, report significant clinical trial results and outline their partnering ambitions — all to potential collaborators. But how do you get seen by the right people?

Small window, big ideas

Big pharma executives are busy people, so with a limited window of opportunity to grab their attention you need to present your company concisely.

This is where Biopharma Dealmakers can help, by working with you to deliver a professionally written piece of branded content. It can help to bring your company’s story to a global community of influential potential partners.

COVID-19 vaccine makers Moderna was one of the first companies Biopharma Dealmakers helped back in 2017 with the piece — mRNA vaccines: potential for global impact — that recounted the company’s progress so far. This early exposure ensured the world knew about Moderna before the global pandemic demonstrated its platform’s lifesaving potential.

The storytelling supports biopharma of all shapes and sizes. Loosening traditional research bottlenecks, Telesis Bio chose Biopharma Dealmakers to describe how it can help researchers create their own DNA in-house overnight. Provirex excited readers by introducing its genome editing technology that could provide a cure for HIV and other virus-related illnesses. Global big pharma can also benefit from the offered services. For example, Biopharma Dealmakers helped GSK to explain why it is a partner of choice to potential partners who are looking for a collaboration of a lifetime.

As well as an unmatchable platform, and alongside experienced scientific writers and editors who can create compelling content, Nature’s Biopharma Dealmakers also provides specialist marketers to strategically target relevant audiences for a company’s therapeutics or technologies.

The service offered by Biopharma Dealmakers forms part of Nature Partnerships, a division of Springer Nature. Nature Partnerships is experienced and known for connecting partners, it provides expert solutions to help companies and other research-led organizations to build their impact and visibility by sharing their stories and beyond. Springer Nature publishes more than 3,000 scholarly journals and has 11+ million readers each month.

If you’re interested in learning more about Biopharma Dealmakers with Nature Partnerships, reach out to our team today.